Results 1 to 10 of about 19,810 (255)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor [PDF]

Clinical Case Reports, 2018
Key Clinical Message This case is a reminder not to overlook rare causes of electrolyte shifts, which may cause reversible changes in pacemaker pacing thresholds.
Stefan Asbach, Fabienne Schluermann, Juri Ruf, Christoph Bode, Corinna Lang   +4 more
doaj   +2 more sources

Kidney Protection with the Radical Scavenger α₁-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy [PDF]

Antioxidants, 2021
α1-Microglobulin (A1M) is an antioxidant found in all vertebrates, including humans. It has enzymatic reductase activity and can scavenge radicals and bind free heme groups.
Amanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, Jonas Ahlstedt, Sven-Erik Strand, Bo Åkerström   +5 more
doaj   +2 more sources

Peptides in receptor-mediated radiotherapy : from design to the clinical application in cancers. [PDF]

Frontiers in Oncology, 2013
Short peptides can show high affinity for specific receptors overexpressed on tumor cells. Some of these are already used in cancerology as diagnostic tools and others are in clinical trials for therapeutic applications. Therefore, peptides exhibit great
Catherine eLOZZA, Isabelle eTEULON, André ePELEGRIN, Jean-Pierre ePOUGET, Eric eVIVES   +4 more
doaj   +4 more sources

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists [PDF]

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

Pharmaceuticals, 2021
Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as
Andrea Cimini, Maria Ricci, Francesca Russo, Martina Egidi, Ferdinando Calabria, Antonio Bagnato, Orazio Schillaci, Agostino Chiaravalloti   +7 more
doaj   +3 more sources

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

PLoS ONE, 2021
Background Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy ...
Daphne M. V. de Vries–Huizing, Michelle W. J. Versleijen, Michiel Sinaasappel, Iris Walraven, Martine M. Geluk–Jonker, Margot E. T. Tesselaar, Jeroen J. M. A. Hendrikx, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel   +8 more
doaj   +3 more sources

Role of 18F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for 177Lu-DOTATATE peptide receptor radionuclide therapy [PDF]

Frontiers in Medicine
BackgroundNeuroblastoma is the most common extracranial solid tumor in children. Peptide receptor radionuclide therapy (PRRT) is a treatment modality with great potential, however, the predictive indicators for its efficacy remain unclear. The aim of the
Yuxuan Liu, Yingying Sun, Yingying Sun, Di Zuo, Han Wang, Fei Zheng, Jingfu Wang, Xiaorong Sun   +7 more
doaj   +2 more sources

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy [PDF]

Frontiers in Oncology
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani   +5 more
doaj   +2 more sources

177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites

World Journal of Nuclear Medicine, 2017
The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor ...
Pradeep Thapa, Rahul Parghane, Sandip Basu   +2 more
doaj   +2 more sources

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy [PDF]

Cancer Imaging, 2020
Background Response after peptide receptor radionuclide therapy (PRRT) can be evaluated using anatomical imaging (CT/MRI), somatostatin receptor imaging ([68Ga]Ga-DOTA-TATE PET/CT), and serum Chromogranin-A (CgA).
Daphne M. V. Huizing, Else A. Aalbersberg, Michelle W. J. Versleijen, Margot E. T. Tesselaar, Iris Walraven, Max J. Lahaye, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel   +7 more
doaj   +2 more sources